Hong-Hong Ning1, Jiong Le2, Qian Wang1, Charlotte Aimee Young3, Bo Deng1, Peng-Xiang Gao1, Hai-Qiao Zhang1, Shu-Lan Qin4. 1. Department of Endocrinology, Third Affiliated Hospital, Nanchang University, 330008, Nanchang, China. 2. Jiangxi Aerospace Icloud Science and Technology Co., Ltd., 330072, Nanchang, China. 3. Department of Ophthalmology, University of California, 94143, San Francisco, CA, USA. 4. Department of Endocrinology, Third Affiliated Hospital, Nanchang University, 330008, Nanchang, China. 1094821826@qq.com.
Abstract
OBJECTIVE: To evaluate the efficacy of metformin versus a placebo in the treatment of patients with simple obesity without obesity related diseases. METHODS: A search was done on Pub-Med, EMBASE, Cochrane, and Science Citation Index Expanded databases. The main inclusion criteria included the following:(1) randomized controlled trials. (2) patients diagnosed as being overweight or obese. (3) patients were randomly assigned to receive metformin or control. Exclusion criteria included the following: patients diagnosed with an obesity related disease, such as diabetes mellitus (DM) or polycystic ovary syndrome (PCOS). RESULTS: Compared with the placebo, weighted mean difference (WMD) was 2.33 (95% CI 0.31, 4.35) kg higher with metformin (p = 0.02). Compared with the placebo, WMD was 0.57 (95% CI 0.35, 0.79) kg/m² higher with metformin(p < 0.00001). There was no significant difference in the reduction of waist circumference between the metformin group and the control group (p = 0.05). The fasting blood glucose levels were significantly lower in the metformin group than in the control group (p < 0.00001). However, no hypoglycemia was noted in the metformin group or the control group. CONCLUSION:Metformin is effective in reducing body weight of simple obesity patients, and metformin does not induce hypoglycemia as a side effect.
RCT Entities:
OBJECTIVE: To evaluate the efficacy of metformin versus a placebo in the treatment of patients with simple obesity without obesity related diseases. METHODS: A search was done on Pub-Med, EMBASE, Cochrane, and Science Citation Index Expanded databases. The main inclusion criteria included the following:(1) randomized controlled trials. (2) patients diagnosed as being overweight or obese. (3) patients were randomly assigned to receive metformin or control. Exclusion criteria included the following: patients diagnosed with an obesity related disease, such as diabetes mellitus (DM) or polycystic ovary syndrome (PCOS). RESULTS: Compared with the placebo, weighted mean difference (WMD) was 2.33 (95% CI 0.31, 4.35) kg higher with metformin (p = 0.02). Compared with the placebo, WMD was 0.57 (95% CI 0.35, 0.79) kg/m² higher with metformin(p < 0.00001). There was no significant difference in the reduction of waist circumference between the metformin group and the control group (p = 0.05). The fasting blood glucose levels were significantly lower in the metformin group than in the control group (p < 0.00001). However, no hypoglycemia was noted in the metformin group or the control group. CONCLUSION:Metformin is effective in reducing body weight of simple obesitypatients, and metformin does not induce hypoglycemia as a side effect.
Entities:
Keywords:
Meta-analysis; Metformin; Obesity; Overweight; Weight loss
Authors: G A Garinis; B Fruci; A Mazza; M De Siena; S Abenavoli; E Gulletta; V Ventura; M Greco; L Abenavoli; A Belfiore Journal: Int J Obes (Lond) Date: 2010-02-23 Impact factor: 5.095
Authors: Nathan T Jenkins; Jaume Padilla; Arturo A Arce-Esquivel; David S Bayless; Jeffrey S Martin; Heather J Leidy; Frank W Booth; R Scott Rector; M Harold Laughlin Journal: J Appl Physiol (1985) Date: 2012-09-27
Authors: Richard Fleming; Zoe E Hopkinson; A Michael Wallace; Ian A Greer; Naveed Sattar Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Emily A Day; Rebecca J Ford; Brennan K Smith; Pedrum Mohammadi-Shemirani; Marisa R Morrow; Robert M Gutgesell; Rachel Lu; Amogelang R Raphenya; Mostafa Kabiri; Andrew G McArthur; Natalia McInnes; Sibylle Hess; Guillaume Paré; Hertzel C Gerstein; Gregory R Steinberg Journal: Nat Metab Date: 2019-12-09